SPX4,132.62+74.78 1.84%
DIA329.99+3.54 1.08%
IXIC12,060.12+319.47 2.72%

U.S. FDA declines to approve third China-tested cancer therapy

U.S. FDA declines to approve third China-tested cancer therapy

reuters.com · 05/02/2022 07:09
U.S. FDA declines to approve third China-tested cancer therapy

- The U.S. drug regulator has declined to approve a cancer drug tested mainly in China, the third rejection of a China-developed drug in a little over a month.

The U.S. Food and Drug Administration issued a complete response letter to the therapy for treating nasopharyngeal carcinoma, a type of head-and-neck cancer, that was developed by U.S.-based Coherus BioSciences Inc CHRS.O and Chinese partner Shanghai Junshi Biosciences Co Ltd 88180.SS, the companies said on Monday. nGNX6QyVNP


(Reporting by Manas Mishra and Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)

((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15; within U.S. +1 646 223 8780;))